clinical trial · NCT03999853
Butyrate Adjuvant Therapy for Type 1 Diabetes
Type1diabetesBKR-017
brief summary
The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
started
Jul 28, 2022
primary completion
Apr 1, 2025
completion
Dec 1, 2025
last updated
Mar 31, 2026
detailed description
This study will test effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy in type 1 diabetes (TID) Subjects on metabolic control in this population. Insulin sensitivity, glucose control (variability) and triglycerides will be measured after 7 weeks of treatment and compared to baseline.
official title
Colonic Delivery of Butyrate to Improve Insulin Sensitivity and Lower Triglycerides in Type 1 Diabetes Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol